What is recorded here?
Reported phase 3 clinical evidence for sofosbuvir-based regimens in previously untreated chronic hepatitis C across multiple viral genotypes, measuring sustained virologic response after therapy.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is the exact 2013 NEJM article and its two open-label trials, regimens and populations. HCV discovery, sofosbuvir chemistry, later interferon-free combinations, approvals, elimination programmes and all HCV genotypes remain separate.
Read the original work
- Lawitz et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- Crossref record for sofosbuvir in untreated HCV
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C. Gordon; Michael Schultz; Mitchell N. Davis; Zeid Kayali; K. Rajender Reddy; Ira M. Jacobson; Kris V. Kowdley; Lisa Nyberg; G. Mani Subramanian; Robert H. Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T. Symonds; John G. McHutchison; Aasim M. Sheikh; Zobair Younossi; Edward J. Gane
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Location not yet established
This record has no published, source-supported geographic mapping yet. Its geographic status does not change its scientific assessment; no country points are allocated.
English catalogue narrative
Lawitz and colleagues: sofosbuvir regimens for previously untreated hepatitis C
Reported phase 3 clinical evidence for sofosbuvir-based regimens in previously untreated chronic hepatitis C across multiple viral genotypes, measuring sustained virologic response after therapy.
Scientific scope
The record is the exact 2013 NEJM article and its two open-label trials, regimens and populations. HCV discovery, sofosbuvir chemistry, later interferon-free combinations, approvals, elimination programmes and all HCV genotypes remain separate.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C. Gordon; Michael Schultz; Mitchell N. Davis; Zeid Kayali; K. Rajender Reddy; Ira M. Jacobson; Kris V. Kowdley; Lisa Nyberg; G. Mani Subramanian; Robert H. Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T. Symonds; John G. McHutchison; Aasim M. Sheikh; Zobair Younossi; Edward J. Gane
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.